title: Positive treatment effect of estradiol in postpartum psychosis: a pilot study.
abstract: BACKGROUND
  Postpartum illnesses with psychiatric symptoms and serious adverse sequelae are highly prevalent during the childbearing years. Despite multiple medical contacts, these illnesses often remain unidentified and untreated. To study the association between estradiol and puerperal psychosis, we measured serum concentration of estradiol and performed an open-label trial of physiologic 17beta-estradiol in women with this disorder.
  
  
  METHODS
  Ten women with ICD-10 psychosis with postpartum onset consecutively recruited from a psychiatric duty unit were studied. Serum estradiol concentration was measured at baseline and weekly during sublingual 17beta-estradiol treatment for 6 weeks. The treatment effect was evaluated by a clinician-rated psychiatric symptom scale (the Brief Psychiatric Rating Scale [BPRS]).
  
  
  RESULTS
  The baseline serum estradiol levels (mean = 49.5 pmol/L; range, 13-90 pmol/L) were even lower than the threshold value of gonadal failure, and the patients exhibited high scores on the psychiatric symptom scale (mean BPRS total score = 78.3; range, 65-87). During the first week of 17beta-estradiol treatment, psychiatric symptoms diminished significantly (BPRS score decreased to a mean of 18.8, p < .001). Until the end of the second week of treatment, serum estradiol concentrations rose to near the values normally found during the follicular phase, and the patients became almost free of psychiatric symptoms.
  
  
  CONCLUSIONS
  The reversal of psychiatric symptoms in all patients by treating documented estradiol deficiency suggests that estradiol plays a role in the pathophysiology and may have a role in the treatment of this condition. There was a rebound of psychotic symptoms in the 1 patient who discontinued estradiol treatment. Given the small number of patients, this area deserves further study.
authors.affiliation: Department of Psychiatry, Helsinki City Hospital, Finland. antti.ahokas@kolumbus.fi
authors.forename: A
authors.initials: A
authors.lastname: Ahokas
authors.forename: M
authors.initials: M
authors.lastname: Aito
authors.forename: R
authors.initials: R
authors.lastname: Rimón
mesh_terms: D000286:Administration, Sublingual; D000328:Adult; D010054:Brief Psychiatric Rating Scale / Q000706:statistics & numerical data; D002940:Circadian Rhythm; D019052:Depression, Postpartum / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy; D004334:Drug Administration Schedule; D004958:Estradiol / Q000008:administration & dosage / Q000097:blood* / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D010865:Pilot Projects; D011618:Psychotic Disorders / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy*; D011644:Puerperal Disorders / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D004958:Estradiol